Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway

BACKGROUND: The cyclooxygenase 2 (COX-2) pathway has been implicated in the molecular pathogenesis of many malignancies, including lung cancer. Apricoxib, a selective COX-2 inhibitor, has been described to inhibit epithelial-mesenchymal transition (EMT) in human malignancies. The mechanism by which...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer Sci Ther
Main Authors: Lee, Mi-Heon, Kachroo, Puja, Pagano, Paul C, Yanagawa, Jane, Wang, Gerald, Walser, Tonya C, Krysan, Kostyantyn, Sharma, Sherven, John, Maie St., Dubinett, Steven M, Lee, Jay M
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624255/
https://ncbi.nlm.nih.gov/pubmed/26523208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4172/1948-5956.1000310
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados